Improvement of the ability of bone repair by reducing the aging degree of mesenchymal stem cell population by Senolytic drugs

In order to study the effects of Senolytic drugs dasatinib and quercetin on the aging of mesenchymal stem cells (MSCs) and explore the application of young MSCs in repairing bone defects, the cultured and identified MSCs were treated with dasatinib and quercetin, counting the number of passage times, and the senescence of cells was evaluated by high-content screening microscopy. The 4th-passage MSCs rejuvenated with Senolytic drugs were transplanted into bone defect model rabbits, and X-ray examination was performed 12 weeks after surgery. The results showed that Senolytic drugs reduced the senility of MSCs and improved the ability of bone repair.